Fieldview Capital Management LLC Invests $5.34 Million in Boston Scientific Corporation $BSX

Fieldview Capital Management LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 54,715 shares of the medical equipment provider’s stock, valued at approximately $5,342,000. Boston Scientific comprises approximately 0.9% of Fieldview Capital Management LLC’s holdings, making the stock its 11th biggest position.

A number of other hedge funds have also recently added to or reduced their stakes in the company. FWL Investment Management LLC bought a new stake in Boston Scientific in the second quarter worth approximately $26,000. Steph & Co. bought a new position in shares of Boston Scientific during the 3rd quarter valued at $25,000. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at $25,000. Finally, United Community Bank lifted its stake in shares of Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Morgan Stanley reduced their price target on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Citigroup decreased their target price on Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. Oppenheimer reduced their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Finally, TD Cowen lowered their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $108.36.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share buyback authorization to $5 billion, which supports EPS and provides a buyback backstop that can limit downside and return capital to shareholders. Boston Scientific (BSX) Raises Share Buyback Authorization To $5B
• Positive Sentiment: Boston Scientific will host an investor event and live webcast at the American College of Cardiology meeting on March 28 to discuss clinical data — a chance for management to highlight growth drivers and reassure investors on clinical/market progress. Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
• Neutral Sentiment: Coverage and commentaries note BSX is about 6% lower since last earnings — analysts point to mixed cues from the earnings release (modest beat on EPS, revenue roughly in line, and guidance ranges) and market reactions to forward views; this helps explain recent selling pressure but is not new company-specific bad news. Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
• Negative Sentiment: A wave of securities-class-action filings and investor-alert notices from multiple law firms allege wrongdoing for purchasers between July 23, 2025 and Feb 3, 2026 — several firms (Robbins LLP, Rosen, Bernstein Liebhard, Faruqi & Faruqi, Levi & Korsinsky, Gainey McKenna & Egleston) have issued notices and reminder deadlines, creating a legal overhang that can pressure the stock and increase uncertainty/costs. BSX Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Rosen Law Firm Urges Boston Scientific Stockholders to Contact the Firm Bernstein Liebhard Investor Alert

Boston Scientific Price Performance

NYSE:BSX opened at $71.24 on Monday. The stock has a market cap of $105.71 billion, a P/E ratio of 36.72, a PEG ratio of 1.00 and a beta of 0.69. Boston Scientific Corporation has a one year low of $70.75 and a one year high of $109.50. The company has a fifty day moving average price of $85.03 and a 200 day moving average price of $94.47. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the business posted $0.70 EPS. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.